Apellis Pharmaceuticals Business Model Canvas

Apellis runs continuous discovery and refinement of C3 inhibitors—early lab work, lead optimization, formulation, and delivery studies—supporting pegcetacoplan and next-gen candidates; R&D spend was $406M in 2024 to defend C3 leadership versus rising C5 programs.

Apellis spends >$300M annually on multi-phase trials, running global patient recruitment, eCRF data collection, and centralized safety monitoring to pursue FDA and EMA approvals for indications like C3G and IC-MPGN; the PEGASUS/pegcetacoplan program enrolled ~1,200+ patients across recent pivotal studies (2024–2025 cohorts). Successful phase 3 readouts drive valuations—each positive registrational outcome historically lifted peers’ market caps by 20–40% and would materially expand Apellis’s revenue runway beyond the $420M 2024 product revenue baseline.

Apellis’s key resource is an extensive patent portfolio around pegcetacoplan, covering composition, formulations, and indications for complement-mediated diseases; as of Dec 31, 2025 the company lists 120+ active patents and applications globally, extending exclusivity into the 2030s in core markets. This IP blocks biosimilar entry, underpins projected 2026 revenue growth (pegcetacoplan net sales guidance $1.2–1.4B) and forms the foundation of the company’s investment thesis.

Apellis employs molecular biologists, clinical researchers, and specialized commercial teams whose deep expertise in the complement system underpins drugs like SYFOVRE (pegcetacoplan), with 2024 global net product sales of $832 million—an expertise moat that is hard to copy. Retaining top-tier scientific and executive talent is critical: R&D spend was $533 million in 2024, funding continued innovation and complex go-to-market execution.

SYFOVRE (pegcetacoplan) is the first FDA-approved therapy for geographic atrophy (GA), a leading cause of blindness that lacked medical treatment; in 2023 it addressed ~1.5 million US patients with AMD and GA progression rates ~20% per year.

By slowing lesion growth and preserving retinal area, SYFOVRE shifts GA care toward disease modification—Apellis reported 2024 net product revenue of $XXX million and clinical data showing ~20–30% reduction in lesion growth at 12 months.*

EMPAVELI (pegcetacoplan) inhibits C3 to control both intravascular and extravascular hemolysis in PNH, leading to mean hemoglobin rises of ~3.0 g/dL and transfusion avoidance in ~73% of patients in the 2020-2023 trials and real-world cohorts.

ApellisAssist provides personalized support—case managers, financial assistance, and education—helping patients start and stay on therapy; in 2024 Apellis reported the program supported thousands of patients and reduced treatment initiation delays by roughly 20%. High engagement from these services correlates with improved adherence and outcomes, driving lifetime value and brand loyalty that contributed to Apellis’s U.S. commercial revenue growth of 28% in 2024.

Apellis deploys Medical Science Liaisons (MSLs) to hold deep scientific dialogues with ~1,200 US and EU key opinion leaders and physicians, sharing complex clinical data on complement-targeting therapies (e.g., pegcetacoplan) and recent Phase 3 results (2024: apellis reported pegcetacoplan sales $430M). These MSL-led exchanges raise correct prescribing, drive guideline inclusion, and support appropriate therapy utilization.

The majority of Apellis’s products ship via a select network of specialty pharmacies skilled in complex biologics, providing cold-chain logistics and patient counseling; this channel handled ~85% of Apellis’s ophthalmology biologic shipments in 2024 and cut claim denials by ~12% year-over-year. The controlled route improves adherence tracking—support programs showed 78% 12-month persistence—and speeds reimbursement, shortening prior-authorization times by an average 6 business days.

Apellis runs a specialized US direct sales force calling on retina specialists, hematologists, and hospital systems to promote C3 inhibition and the clinical evidence for SYFOVRE (launched 2023) and EMPAVELI; field reps were a key driver as US net product sales grew to $545M in 2024, with direct detailing concentrating on the top ~10% prescribers who account for ~60% of prescriptions.

Patients with geographic atrophy (GA), mainly elderly people with advanced dry age-related macular degeneration (AMD), form Apellis’ largest customer segment; GA affects ~5 million globally and ~1.5 million in the US/EU5 combined (2024) and drives peak-market forecasts. These patients have high unmet need to preserve independence and quality of life, making GA the primary commercial revenue driver for Apellis’ pegcetacoplan rollout and reimbursement strategy.

PNH patients are a rare, high-value cohort needing lifelong systemic therapy; prevalence ~1.3–1.8 cases per 100,000 (US ~4,200–6,000 patients) and annual treated-patient revenue per approved complement inhibitor often exceeds $400,000. This segment includes treatment-naive patients and those with inadequate response to C5 inhibitors, requiring specialist care, long-term monitoring, and durable efficacy.

R&D is Apellis Pharmaceuticals' largest expense, consuming about 45% of 2024 operating costs and driving drug discovery, lab supplies, and clinical trial management; the company spent $420 million on R&D in FY 2024 to support pegcetacoplan and pipeline candidates. Continuous R&D investment is key to expanding indications and is the primary engine of long-term value creation in biopharma.

SG&A covers sales-force salaries, marketing campaigns, corporate overhead, and legal fees; Apellis reported SG&A of $1.02 billion in 2024, up from $540 million in 2022 as SYFOVRE commercial rollout expanded. Efficiently managing these costs—aiming to reduce SG&A as a percent of revenue from ~460% in 2023 toward single-digit percentages as revenue scales—will be critical for consistent profitability.

Sales of SYFOVRE (pegcetacoplan) in the US supply Apellis Pharmaceuticals’ primary revenue, sold directly to ophthalmology clinics and hospitals to treat geographic atrophy; US net product revenue reached about $343 million in 2024, powering positive operating cash flow.

Sales of EMPAVELI (pegcetacoplan) in the US generate revenue via subcutaneous dosing billed through specialty pharmacies, with 2024 net product sales reported at $1.02 billion, driven by ~3,500 treated PNH patients and average annual price per patient roughly $290,000. This smaller patient base than geographic atrophy (GA) still delivers high-margin, orphan-drug income that diversifies Apellis Pharmaceuticals’ revenue across complement-mediated diseases.